Insider filing · CGEM

Lynx1 Capital Management LP bought $9.8M of Cullinan Therapeutics (CGEM)

Executed Oct 8 2025, disclosed Oct 10 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Oct 10 2025), the stock returned +1.3% (delay-adjusted); from the execution session (Oct 8 2025), +24.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

LL Lynx1 Capital Management LP 10% owner profile →

Lynx1 Capital Management LP (10% owner) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Passage Bio, Inc. (PASG). Across 5 priced purchase filings, the average 21-session return was +14.0% from execution and +10.1% from disclosure (delay-adjusted; derived). The largest single filing was $9.8M of CGEM (1,459,641 sh across 3 lots, as filed), executed Oct 8 2025.

CGEM Cullinan Therapeutics, Inc. CGEM · Healthcare · 13 filings in 24 months ticker →

Healthcare · Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the Unite…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→